Miraculins Announces First Closing of Private Placement Offering

Miraculins Announces First Closing of Private Placement Offering

ID: 429476

(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 10/26/15 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces the first closing of a non-brokered private placement offering (the "Offering") of up to 5,000,000 units ("Units") at a price of $0.05 per Unit for gross proceeds of up to $250,000. Each Unit is comprised of one common share of the Company (a "Share") and one-half of one Share purchase warrant. Each whole warrant (a "Warrant") entitles the holder to purchase one Share at a price of $0.08 per Share for a period of 12 months from the date the Warrant is issued. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws. The first closing brought in aggregate gross proceeds of $135,000 from the sale of 2,700,000 Units.

A certain person assisted the Company by introducing a subscriber for the Offering and was paid a finder's fee of 10% of the total subscription proceeds received from the subscriber introduced to the Company by that person.

The net proceeds of the Offering will be used for general corporate purposes.

The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Bereitgestellt von Benutzer: Marketwired
Datum: 26.10.2015 - 22:59 Uhr
Sprache: Deutsch
News-ID 429476
Anzahl Zeichen: 0

contact information:
Town:

WINNIPEG, MANITOBA



Kategorie:

Drugs



Diese Pressemitteilung wurde bisher 272 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Miraculins Announces First Closing of Private Placement Offering"
steht unter der journalistisch-redaktionellen Verantwortung von

Miraculins Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Miraculins Announces Unsecured Non-Convertible Loans ...

WINNIPEG, MANITOBA -- (Marketwired) -- 12/08/15 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for ...

Miraculins Announces Extension of Secured Loans ...

WINNIPEG, MANITOBA -- (Marketwired) -- 11/23/15 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for ...

Miraculins Announces Strategic Review Process ...

WINNIPEG, MANITOBA -- (Marketwired) -- 11/11/15 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for ...

Alle Meldungen von Miraculins Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z